Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros












Base de dados
Intervalo de ano de publicação
1.
AIDS Res Hum Retroviruses ; 39(7): 318-331, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36825522

RESUMO

Revolutionary progress in combinational antiretroviral therapy has transformed human immunodeficiency virus (HIV) infection into a chronic manageable disease; yet, there exists an uneasy truce between the virus and the immune cells, where inflammation is limited but infection continues to fester from latent reservoirs of the virus. Clinical studies have identified the major immune cell types that constitute the latent HIV-1 reservoirs as monocytes/macrophages and CD4+ T cells. Latency probing approaches have thrown some light on the interaction between the virus and the reservoir cells from the time of onset of infection. However, research combining latency reversal strategies and immunotherapies face daunting obstacles in clinical trials because of the lack of in-depth knowledge on viral pathogenesis and mechanisms of viral evasion, leaving us behind in the battle for HIV cure. This article reviews existing knowledge on the cells and mechanisms that contribute to the establishment and survival of HIV reservoirs in infected individuals.


Assuntos
Infecções por HIV , HIV-1 , Humanos , Infecções por HIV/tratamento farmacológico , Latência Viral , Macrófagos , Linfócitos T CD4-Positivos , Replicação Viral
2.
BMC Immunol ; 23(1): 51, 2022 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-36289478

RESUMO

BACKGROUND: Plasmacytoid and myeloid dendritic cells play a vital role in the protection against viral infections. In COVID-19, there is an impairment of dendritic cell (DC) function and interferon secretion which has been correlated with disease severity. RESULTS: In this study, we described the frequency of DC subsets and the plasma levels of Type I (IFNα, IFNß) and Type III Interferons (IFNλ1), IFNλ2) and IFNλ3) in seven groups of COVID-19 individuals, classified based on days since RT-PCR confirmation of SARS-CoV2 infection. Our data shows that the frequencies of pDC and mDC increase from Days 15-30 to Days 61-90 and plateau thereafter. Similarly, the levels of IFNα, IFNß, IFNλ1, IFNλ2 and IFNλ3 increase from Days 15-30 to Days 61-90 and plateau thereafter. COVID-19 patients with severe disease exhibit diminished frequencies of pDC and mDC and decreased levels of IFNα, IFNß, IFNλ1, IFNλ2 and IFNλ3. Finally, the percentages of DC subsets positively correlated with the levels of Type I and Type III IFNs. CONCLUSION: Thus, our study provides evidence of restoration of homeostatic levels in DC subset frequencies and circulating levels of Type I and Type III IFNs in convalescent COVID-19 individuals.


Assuntos
COVID-19 , Interferon Tipo I , Humanos , Interferon Tipo I/metabolismo , RNA Viral/metabolismo , SARS-CoV-2 , Células Dendríticas/metabolismo , Homeostase
3.
Vaccines (Basel) ; 10(6)2022 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-35746578

RESUMO

We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine's effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6-73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.

4.
Pathogens ; 10(4)2021 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-33915946

RESUMO

In April 2016, an indigenous monovalent rotavirus vaccine (Rotavac) was introduced to the National Immunization Program in India. Hospital-based surveillance for acute gastroenteritis was conducted in five sentinel sites from 2012 to 2020 to monitor the vaccine impact on various genotypes and the reduction in rotavirus positivity at each site. Stool samples collected from children under 5 years of age hospitalized with diarrhea were tested for group A rotavirus using a commercial enzyme immunoassay, and rotavirus strains were characterized by RT-PCR. The proportion of diarrhea hospitalizations attributable to rotavirus at the five sites declined from a range of 56-29.4% in pre-vaccine years to 34-12% in post-vaccine years. G1P[8] was the predominant strain in the pre-vaccination period, and G3P[8] was the most common in the post-vaccination period. Circulating patterns varied throughout the study period, and increased proportions of mixed genotypes were detected in the post-vaccination phase. Continuous long-term surveillance is essential to understand the diversity and immuno-epidemiological effects of rotavirus vaccination.

6.
Rev Iberoam Micol ; 23(2): 101-3, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16854187

RESUMO

A total of 149 clinical isolates of Candida species isolated from immunocompromised patients were examined to ascertain their esterase activity by the Tween 80 opacity test, which is a biochemical test used mainly to differentiate between Candida albicans and Candida dubliniensis. Our results showed that C. albicans (92.3%), Candida tropicalis (92.3%), Candida parapsilosis (25%), C. dubliniensis (16.6%), Candida inconspicua (100%), and Candida lipolytica (100%) produced opacity halos through the 10-day post-inoculation period. The remaining Candida species did not produce a positive test response. These findings indicate that Tween 80 opacity test cannot be used as the sole phenotypic trait in the differentiation of C. albicans and C. dubliniensis.


Assuntos
Candida/enzimologia , Candidíase/microbiologia , Esterases/análise , Proteínas Fúngicas/análise , Candida/classificação , Candida/isolamento & purificação , Precipitação Química , Meios de Cultura/metabolismo , Esterases/metabolismo , Proteínas Fúngicas/metabolismo , Humanos , Hidrólise , Hospedeiro Imunocomprometido , Luz , Fenótipo , Polissorbatos/metabolismo , Espalhamento de Radiação , Especificidade da Espécie
7.
Jpn J Infect Dis ; 58(4): 218-21, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16116254

RESUMO

Candida spp. are recognized as a leading contributor to mortality and morbidity in patients with onco-hematological malignancies. The rates and risk factors for mycotic infections in pediatric oncology patients are undetermined, particularly for those treated at centers in developing countries. The objective of the present study was to prospectively evaluate the species stratification and antifungal susceptibility profile of Candida spp. associated with superficial and systemic infection in children with onco-hematological diseases. Acute lymphoblastic leukemia was the most common underlying disease (71.4%) among the 91 children under study. Candida albicans was the predominant species, with 17/29 isolates (58.6%); followed by C. tropicalis, with 10/29 isolates (34.5%). The drug susceptibility data analysis for the clinical isolates of Candida revealed 17.2% (5/29) resistance to fluconazole. This study reinforces the need for the systematic surveillance of candidosis for the correct management of such life-threatening infections.


Assuntos
Candida , Candidíase/epidemiologia , Neoplasias Hematológicas/epidemiologia , Superinfecção/epidemiologia , Antifúngicos/farmacologia , Candida/efeitos dos fármacos , Candida/isolamento & purificação , Candidíase/etiologia , Criança , Estudos de Coortes , Farmacorresistência Fúngica , Feminino , Fluconazol/farmacologia , Neoplasias Hematológicas/complicações , Humanos , Índia/epidemiologia , Leucemia Linfoide/complicações , Leucemia Linfoide/epidemiologia , Masculino , Estudos Prospectivos , Especificidade da Espécie , Superinfecção/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...